Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 747

1.

Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.

Nijhuis M, van Maarseveen NM, Boucher CA.

Handb Exp Pharmacol. 2009;(189):299-320. doi: 10.1007/978-3-540-79086-0_11. Review.

PMID:
19048205
[PubMed - indexed for MEDLINE]
2.

Hepatitis B virus mutations associated with antiviral therapy.

Bartholomeusz A, Locarnini S.

J Med Virol. 2006;78 Suppl 1:S52-5.

PMID:
16622878
[PubMed - indexed for MEDLINE]
3.

The emerging field of HCV drug resistance.

Koev G, Kati W.

Expert Opin Investig Drugs. 2008 Mar;17(3):303-19. doi: 10.1517/13543784.17.3.303 . Review.

PMID:
18321230
[PubMed - indexed for MEDLINE]
4.

Resistance mechanisms in HCV: from evolution to intervention.

Kim AY, Timm J.

Expert Rev Anti Infect Ther. 2008 Aug;6(4):463-78. doi: 10.1586/14787210.6.4.463. Review.

PMID:
18662114
[PubMed - indexed for MEDLINE]
5.

Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?

Zoulim F.

Antivir Chem Chemother. 2004 Nov;15(6):299-305. Review.

PMID:
15646643
[PubMed - indexed for MEDLINE]
6.

Antiviral therapy targeting viral polymerase.

Tsai CH, Lee PY, Stollar V, Li ML.

Curr Pharm Des. 2006;12(11):1339-55. Review.

PMID:
16611119
[PubMed - indexed for MEDLINE]
7.

Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.

Locarnini S, Warner N.

Antivir Ther. 2007;12 Suppl 3:H15-23. Review.

PMID:
18284179
[PubMed - indexed for MEDLINE]
8.

Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.

Buckheit RW Jr.

Expert Opin Investig Drugs. 2004 Aug;13(8):933-58. Review.

PMID:
15268633
[PubMed - indexed for MEDLINE]
9.

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.

Guedj J, Neumann AU.

J Theor Biol. 2010 Dec 7;267(3):330-40. doi: 10.1016/j.jtbi.2010.08.036. Epub 2010 Sep 8.

PMID:
20831874
[PubMed - indexed for MEDLINE]
10.

A perspective on antiviral resistance.

Griffiths PD.

J Clin Virol. 2009 Sep;46(1):3-8. doi: 10.1016/j.jcv.2009.06.017. Epub 2009 Jul 16. Review.

PMID:
19615937
[PubMed - indexed for MEDLINE]
11.

The concept of hepatitis B virus mutant escape.

Pawlotsky JM.

J Clin Virol. 2005 Dec;34 Suppl 1:S125-9. Review.

PMID:
16461211
[PubMed - indexed for MEDLINE]
12.

Antiviral drug resistance.

Richman DD.

Antiviral Res. 2006 Sep;71(2-3):117-21. Epub 2006 Mar 30. Review.

PMID:
16621040
[PubMed - indexed for MEDLINE]
13.

Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.

Ferraris O, Kessler N, Valette M, Lina B.

Vaccine. 2006 Nov 10;24(44-46):6656-9. Epub 2006 Jun 8.

PMID:
16797804
[PubMed - indexed for MEDLINE]
14.

Antiviral strategies.

Müller B, Kräusslich HG.

Handb Exp Pharmacol. 2009;(189):1-24. doi: 10.1007/978-3-540-79086-0_1. Review.

PMID:
19048195
[PubMed - indexed for MEDLINE]
15.

Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.

Hurt AC, Ho HT, Barr I.

Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. Review.

PMID:
17140356
[PubMed - indexed for MEDLINE]
16.

Mode of selection and experimental evolution of antiviral drugs resistance in vesicular stomatitis virus.

Cuevas JM, Sanjuán R, Moya A, Elena SF.

Infect Genet Evol. 2005 Jan;5(1):55-65.

PMID:
15567139
[PubMed - indexed for MEDLINE]
17.

Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.

Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W.

Clin Ther. 2009 Feb;31(2):360-6. doi: 10.1016/j.clinthera.2009.02.016.

PMID:
19302908
[PubMed - indexed for MEDLINE]
18.

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Zürcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL.

J Antimicrob Chemother. 2006 Oct;58(4):723-32. Epub 2006 Aug 5.

PMID:
16891631
[PubMed - indexed for MEDLINE]
Free Article
19.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.

Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.

Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

PMID:
17888524
[PubMed - indexed for MEDLINE]
20.

Mutations affecting the replication capacity of the hepatitis B virus.

Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V.

J Viral Hepat. 2006 Jul;13(7):427-34. Review.

PMID:
16792535
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk